Brian A Leuthner insider trades: ONCOSEC MEDICAL (ONCS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Brian reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 28, 2021 | ONCS | ↓ Sell | 13,613 | $3.16 | $43K | Direct | Jun 29, 2021 (1d) |
| Mar 2, 2018 | EDGE | ↓ Sell | 5,000 | $14.95 | $75K | Direct | Mar 5, 2018 (3d) |
| Feb 23, 2018 | EDGE | ↓ Sell | 5,000 | $15.42 | $77K | Direct | Feb 23, 2018 (0d) |
| Feb 2, 2018 | EDGE | ↓ Sell | 5,000 | $13.05 | $65K | Direct | Feb 2, 2018 (0d) |
| Jan 3, 2018 | EDGE | ↓ Sell | 5,000 | $10.11 | $51K | Direct | Jan 3, 2018 (0d) |
| Dec 5, 2017 | EDGE | ↓ Sell | 7,500 | $9.86 | $74K | Direct | Dec 5, 2017 (0d) |
| Nov 3, 2017 | EDGE | ↓ Sell | 7,500 | $10.91 | $82K | Direct | Nov 3, 2017 (0d) |
| Oct 4, 2017 | EDGE | ↓ Sell | 7,500 | $10.96 | $82K | Direct | Oct 4, 2017 (0d) |
| Sep 6, 2017 | EDGE | ↓ Sell | 7,500 | $10.21 | $77K | Direct | Sep 6, 2017 (0d) |
| Aug 3, 2017 | EDGE | ↓ Sell | 7,500 | $10.53 | $79K | Direct | Aug 3, 2017 (0d) |
| Jul 6, 2017 | EDGE | ↓ Sell | 7,500 | $10.19 | $76K | Direct | Jul 6, 2017 (0d) |
| Apr 26, 2017 | EDGE | ↓ Sell10b5-1 | 100 | $11.10 | $1K | Direct | May 9, 2017 (13d) |
| Feb 7, 2017 | EDGE | ↓ Sell | 1,500 | $9.52 | $14K | Direct | Feb 8, 2017 (1d) |
| Feb 6, 2017 | EDGE | ↓ Sell | 3,000 | $9.61 | $29K | Direct | Feb 7, 2017 (1d) |
| Feb 2, 2017 | EDGE | ↓ Sell | 3,000 | $9.49 | $28K | Direct | Feb 3, 2017 (1d) |
| Dec 1, 2016 | EDGE | ↓ Sell | 7,500 | $11.60 | $87K | Direct | Dec 2, 2016 (1d) |
| Oct 3, 2016 | EDGE | ↓ Sell | 7,500 | $10.25 | $77K | Direct | Oct 4, 2016 (1d) |
| Aug 1, 2016 | EDGE | ↓ Sell | 7,500 | $9.54 | $72K | Direct | Aug 2, 2016 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Brian A Leuthner's insider trades
Brian A Leuthner is Interim CEO at ONCOSEC MEDICAL (ONCS). Since Aug 1, 2016, Brian has reported no open-market purchases and 18 sales worth $1.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (0% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (7 filings), option exercises (1 filing), conversions (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONCS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.